Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensory Attributes of Loratadine Chewable Tablet
NCT04162795Phase 4Completed
- Sponsor
- Bayer
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of loratadine in allergic rhinitis (AR), sponsored by Bayer. Primary endpoint: Proportion of Participants With Agreement of Perception of Cooling Sensation. Started Nov 2019; status: completed.
02
Drugs
loratadine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04162795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162795.